Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
J. Alder, R. Wilson, T. Welte, E. Polverino, A. De Soyza, H. Greville, A. O‘Donnell, P. Reimnitz, B. Hampel (Montville, Washington, United States Of America; London, Newcastle upon Tyne, United Kingdom; Hannover, Wuppertal, Berlin, Germany; Barcelona, Spain; Adelaide, Australia). Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis. Eur Respir J 2011; 38: Suppl. 55, 1930

Member's Comments

No comment yet.

Related content which might interest you: Efficacy and safety of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis Year: 2011 Evaluation of inhaled dry powder tobramycin free base in non-cystic fibrosis bronchiectasis patients Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections Year: 2016 Health status impact of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2011 - Pseudomonas aeruginosa infection and non-cystic fibrosis bronchiectasis Year: 2011 In vitro evaluation of the Twincer colistin dry powder inhaler as a non-cough-inducing alternative to Colobreathe Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections Year: 2016 Long-term administration of aerosolised tobramycin in patients with cystic fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 619s Year: 2005 Aerozolized colistin therapy in non-cystic fibrosis patients with bronchiectasis Source: Eur Respir J 2001; 18: Suppl. 33, 266s Year: 2001 Efficacy of inhaled dry powder tobramycin (TOBI Podhaler) in P. aeruginosa infected patients with bronchiectasis - iBEST study Source: Virtual Congress 2020 – Bronchiectasis: epidemiology, endotyping and therapy Year: 2020 Once-daily tobramycin in the treatment of adult patients with cystic fibrosis Source: Eur Respir J 2002; 19: 303-309 Year: 2002 Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis Source: Eur Respir Rev 2013; 22: 476-486 Year: 2013 Daily versus weekly azithromycin in cystic fibrosis patients Source: Eur Respir J 2007; 30: 487-495 Year: 2007 Effects of long-term azithromycin treatment in patients with non-cystic fibrosis stable bronchiectasis Source: Annual Congress 2007 - Infectious lung and pleural diseases Year: 2007 Distribution of nebulised gentamicin in patients with bronchiectasis Source: Eur Respir J 2004; 24: Suppl. 48, 640s Year: 2004 Resistance to antimicrobial agents in patients with non-cystic fibrosis (CF) bronchiectasis Source: Eur Respir J 2005; 26: Suppl. 49, 640s Year: 2005 Adherence with inhaled colistimethate sodium during a 6 month study in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2013 –Treating bronchiectasis in respiratory patients Year: 2013 Effects of long term low dose azithromycin in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2010 - New aspects of treatment of lower respiratory tract infections Year: 2010 Inhaled antibiotics in non-cystic fibrosis bronchiectasis: better than oral antibiotics? Source: International Congress 2016 – PG13 Inhaled antibiotics in respiratory infections Year: 2016 Effect of azithromycin on FEV1 and exacerbation frequency in adult non-cystic fibrosis bronchiectasis Source: Eur Respir J 2007; 30: Suppl. 51, 528s Year: 2007 A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis Source: Eur Respir J 2002; 20: 658-664 Year: 2002 Efficacy of ciprofloxacin against resistant mucoid or non-mucoid P. aeruginosa isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Safety and pharmacokinetics of multiple-dose ciprofloxacin dry powder for inhalation in patients with moderate or severe COPD Source: Annual Congress 2011 - Role of infection in exacerbations of COPD Year: 2011